ProMIS Neurosciences Secures $175M PIPE Financing, Funds Fully Enrolled Phase 1b Trial
ProMIS Neurosciences raised $175 million in PIPE financing to fund its fully enrolled 144-participant Phase 1b PRECISE-AD trial and operations through 2027. A blinded six-month interim analysis of safety and biomarker trends is due early Q3 2026, with unblinded 12-month top-line data expected early 2027.
1. PIPE Financing Details
ProMIS Neurosciences closed a PIPE financing round in February 2026, raising gross proceeds of $75.5 million with the potential to secure an additional $100 million upon warrant exercise, bringing total funding capacity to $175 million. These proceeds are expected to fund corporate operations and the fully enrolled Phase 1b PRECISE-AD trial through 2027.
2. Phase 1b PRECISE-AD Trial Progress
The PRECISE-AD trial is fully enrolled with 144 participants across three dosing cohorts receiving treatment over 12 months. A blinded interim analysis of aggregated safety data and key biomarker trends is anticipated in early Q3 2026, and full 12-month top-line results are expected in early 2027, preserving blind integrity while providing early target engagement insights.
3. PMN310 Mechanism and Safety Profile
PMN310 is designed to selectively target toxic soluble amyloid-beta oligomers while sparing plaque, aiming to reduce the incidence of amyloid-related imaging abnormalities (ARIA) seen with plaque-directed antibodies. The company has also accelerated development of a subcutaneous formulation to enhance patient convenience and strengthen the candidate’s competitive profile.
4. Pipeline Progress and Upcoming Milestones
ProMIS presented new discovery platform data at the AD/PD 2026 conference and participated in healthcare investor events, highlighting its vaccine programs against TDP-43 and alpha-synuclein. The company expects to complete patient dosing by year-end 2026 and will report unblinded safety, biomarker, and clinical outcomes by treatment group in early 2027.